Search results
Jun 24, 2024 · Driven by our collective vision of transforming healthcare and transforming patients’ lives, Biocon Biologics is making healthcare affordable and importantly accessible to millions of patients and their families across the world.
Biocon Biologics is today one of the frontrunners in the global biosimilars industry, working to provide patients access to affordable biologics and enable health equity worldwide. Driven by a Purpose to Address Unmet Needs for Affordable Biologics.
Biocon is an innovation led fully integrated biopharmaceutical company that develop affordable biosimilars, generic formulations & complex APIs.
Biocon Biologics Limited (BBL) is a fully integrated, innovation-led company committed to transforming patients’ lives by enabling affordable access to high-quality biosimilars for patients and healthcare systems, either directly or through a network of partners and distributors, in over 100+ countries.
Biocon Biologics Limited, a subsidiary of Biocon Limited, is a fully integrated global biosimilars organization. It is leveraging cutting-edge science, innovative tech platforms and...
Biocon Biologics Limited (BBL) is a subsidiary of the publicly listed Biocon Limited, which operates its biosimilars business through BBL. Please refer to the Investors’ Section of Biocon Limited for all statutory information.
The Board of Directors hereby present the 6th Annual Report on the business and operations of Biocon Biologics Limited, formerly known as Biocon Biologics India Limited (“the Company”) together with the audited standalone and consolidated financial
Jun 24, 2024 · Biocon Biologics is an international fully integrated biosimilar subsidiary of listed Biocon Limited. Biocon Biologics offers a portfolio of eight commercialised biosimilars across the globe which include Insulin Glargine, Insulin Aspart, recombinant Human Insulin, Trastuzumab, Bevacizumab, Pegfilgrastim, Adalimumab and Etanercept. The company expects to include 20 biosimilar assets across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases. ...
May 28, 2023 · Biocon Biologics Ltd (BBL) has ended financial year 2023 (FY23) on a high. The year marks an inflection point in its value creation journey as the acquisition of partner Viatris’ biosimilars business has catapulted the company into the global big league.
Find out what works well at Biocon Biologics Limited from the people who know best. Get the inside scoop on jobs, salaries, top office locations, and CEO insights. Compare pay for popular roles and read about the team’s work-life balance.
